Search
for

    Learn

    5 / 801 results

    Research

    5 / 1000+ results
      Current Evaluation of Amenorrhea

      research Current evaluation of amenorrhea

      78 citations , November 2008 in “Fertility and Sterility”
      Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.
      Current Evaluation of Amenorrhea

      research Current evaluation of amenorrhea

      38 citations , October 2006 in “Fertility and Sterility”
      The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.
      Current Evaluation of Amenorrhea

      research Current evaluation of amenorrhea

      30 citations , July 2004 in “Fertility and Sterility”
      Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.
      Current Evaluation of Amenorrhea

      research Current evaluation of amenorrhea

      21 citations , September 2004 in “Fertility and Sterility”
      Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

    Community Join

    5 / 1000+ results

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  7 upvotes 9 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community Mechanism of action of alfatradiol (17 alpha estradiol)

      in Research/Science  5 upvotes 1 year ago
      The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

      community What happens if you combine dutasteride and a aromataze inhibitor?

      in Question  4 upvotes 6 years ago
      Combining dutasteride and an aromatase inhibitor may increase testosterone levels significantly, potentially enhancing athletic performance but also posing health risks like elevated blood pressure and worsened cholesterol. The user is experimenting with dutasteride, anastrozole, minoxidil, and ketoconazole shampoo to manage hair loss and estradiol levels, while monitoring side effects and hormone levels.

      community Methods Of Staying Safe On Ru58841 - My 2 Cents

      in Research/Science  21 upvotes 1 year ago
      RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.